VAERS Explorer
Back to explore

Report #2888908

Received Mar 13, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
NJ
Recovered
Not recovered
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (PFIZER-BIONTECH))PFIZER\BIONTECHUNK

Symptoms (2)

EczemaImmune system disorder

Symptom narrative

patient developed a non-serious immune system being messed up got "wrecked (immune system disorder; "still experiencing "very bad eczema"; This is a spontaneous report received from an Other HCP. A 63-year-old male patient received BNT162b2 (BNT162B2 NOS), in 2024 as dose number unknown, singlen (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPILUMAB), in 2023 as 300 mg (qow (every 2 weeks)) (Lot number: 5F749A, Expiration Date: 31Jan2028) for eczema. The patient's relevant medical history included: "Eczema", start date: 2023 (ongoing). The patient's concomitant medications were not reported. The following information was reported: IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "patient developed a non-serious immune system being messed up got "wrecked (immune system disorder"; ECZEMA (non-serious), outcome "not recovered", described as ""still experiencing "very bad eczema"". The action taken for dupilumab was unknown. Additional information: The patient, whose immune system had been compromised, got wrecked and still experienced very bad eczema due to the immune system being compromised while receiving the COVID-19 vaccine and while being treated with DUPILUMAB delivered via Dupixent single-dose pre-filled pen. In 2024, the patient received a dose of the suspect COVID-19 vaccine not produced by Sanofi Pasteur, with the lot number not reported, via an unknown route and administration site. On an unknown date, the patient developed a non-serious immune system disorder described as "wrecked" (unknown latency) following the first dose of DUPILUMAB. On an unknown date, the patient developed a event of still experiencing very bad eczema due to the compromised immune system (therapeutic response decreased, unknown latency) following the first dose of DUPILUMAB. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.

Current illness

Eczema